alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9285 Automated cell-washing centrifuge for immuno-hematology. ( a ) *Identification.* An automated cell-washing centrifuge for immuno-hematology is a device used to separate and prepare cells and sera for further in vitro diagnostic testing.
( b ) *Classification.* Class II (performance standards).
[45 FR 60646, Sept. 12, 1980]
§ 582.7187 Calcium alginate. ( a ) *Product.* Calcium alginate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10345-10346]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4534]


-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

United States Mint


Pricing for 2010 United States Mint America the Beautiful 
Quarters Proof Set, etc.

AGENCY: United States Mint, Department of the Treasury.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The United States Mint is announcing the prices of the 2010 
United States Mint America the Beautiful Quarters Proof Set; 2010 
United States Mint America the Beautiful Quarters Silver Proof Set; 
2010 United States Mint Uncirculated Coin Set; 2010 United States Mint 
Proof Set; and 2010 United States Mint Silver Proof Set.
    The 2010 United States Mint America the Beautiful Quarters Proof 
Set will be priced at $14.95.
    The 2010 United States Mint America the Beautiful Quarters Silver 
Proof Set will be priced at $32.95.
    The 2010 United States Mint Uncirculated Coin Set will be priced at 
$31.95.
    The 2010 United States Mint Proof Set will be priced at $31.95.
    The 2010 United States Mint Silver Proof Set will be priced at 
$56.95.
    The release dates for these sets will be available on the United 
States Mint Web site at www.usmint/catalog.

FOR FURTHER INFORMATION CONTACT: B. B. Craig, Associate Director for 
Sales and

[[Page 10346]]

Marketing; United States Mint; 801 9th Street, NW., Washington, DC 
20220; or call 202-354-7500.

    Authority: 31 U.S.C. 5111, 5112 & 9701.

    Dated: February 26, 2010.
Edmund C. Moy,
Director, United States Mint.
[FR Doc. 2010-4534 Filed 3-4-10; 8:45 am]
BILLING CODE P
Court of Appeals of the State of Georgia

Clerk's Office, Atlanta, May 05, 2016.

I certify that the above is a true extract from the minutes of

the Court of Appeals of Georgia.

Witness my signature and the seal of said court hereto

affixed the day and year last above written.

, Clerk.

Court of Appeals 

of the State of Georgia

ATLANTA, May 05, 2016

The Court of Appeals hereby passes the following order

A16D0336. FRANCHESKA E. LEWIS v. DEDA ALLEN.

Upon consideration of the Application for Discretionary Appeal, it is ordered that it be

hereby GRANTED. The Appellant may file a Notice of Appeal within 10 days of the date of this

order. The Clerk of Superior Court is directed to include a copy of this order in the record

transmitted to the Court of Appeals.

LC NUMBERS:

2013/2016DR1245
§ 582.6810 Sodium tripolyphosphate. ( a ) *Product.* Sodium tripolyphosphate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<PAGE>

                                                                   Exhibit 10.31

[LOGO OF HOME PRODUCTS INTERNATIONAL.]

                                                            EXECUTIVE MEMORANDUM

JAMES R. TENNANT

         DATE: August 23, 2001

         TO: Joe Lacambra

         SUBJECT: Severance

         In connection with your annual review which we have just completed, and
         per our agreement, this memo details your severance arrangement with
         HPI.

         In the event that you are terminated without cause, your severance will
         be six months of your annual base salary paid out over six months
         through normal payroll.

         /s/ James R. Tennant
Exhibit 99.2
                                  ------------



           CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
           -----------------------------------------------------------
            PURSUANT BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
            ---------------------------------------------------------

         In connection with the Quarterly Report of Roast-N-Roll  Restaurants of
the Past,  Inc.,  on Form 10-QSB for the period  ending  March 31, 2003 as filed
with the  Securities ad Exchange  commission on the date hereof (the  "Report"),
the  undersigned,   Nick  Bruzesse  Jr.   Secretary/Treasurer  of  the  Company,
certifies,  pursuant to 18 U.S.C.  Section 1350, as adopted  pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:

         (1)  The Report fully complies with the  requirements of section 13 (a)
              or 15 (d) of the Securities Exchange Act of 1934; and

         (2)  The information  contained in the Report fairly  presents,  in all
              material   respects,   the  financial   condition  and  result  of
              operations of the Company.

Date: May 20, 2003

                                                     /s/ Nick Bruzesse, Jr.
                                                     ----------------------
                                                     Nick Bruzesse, Jr.
                                                     Secretary/Treasurer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM A FORM
10-QSB FOR THE QUARTER ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FORM 10-QSB.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                       4,529,310
<SECURITIES>                                 1,561,606
<RECEIVABLES>                                1,153,104
<ALLOWANCES>                                         0
<INVENTORY>                                    888,959
<CURRENT-ASSETS>                             8,185,341
<PP&E>                                       6,873,455
<DEPRECIATION>                               2,250,897
<TOTAL-ASSETS>                              12,811,649
<CURRENT-LIABILITIES>                          772,500
<BONDS>                                      1,208,783
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     6,509,267
<OTHER-SE>                                   4,073,326
<TOTAL-LIABILITY-AND-EQUITY>                12,811,649
<SALES>                                      2,272,286
<TOTAL-REVENUES>                             2,272,286
<CGS>                                        1,136,756
<TOTAL-COSTS>                                  909,618
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              25,433
<INCOME-PRETAX>                                308,266
<INCOME-TAX>                                   119,400
<INCOME-CONTINUING>                            188,866
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   188,866
<EPS-BASIC>                                        .04
<EPS-DILUTED>                                      .04


</TABLE>
# C_2014235EN.01002902.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/29 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/29

---

Action brought on 21 May 2014 — Lidl Stiftung v OHIM (Deluxe)

(Case T-344/14)

2014/C 235/40

Language of the case: German

Parties

Parties

Applicant: Lidl Stiftung & Co. KG (Neckarsulm, Germany) (represented by M. Kefferpütz and A. Wrage, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 6 March 2014 in Case R 1223/2013-1; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 6 March 2014 in Case R 1223/2013-1;

| — | Declare that the provisions of Article 7(1)(b) and Article 7(2) of Regulation No 207/2009 do not preclude the publication of the mark applied for; |
| --- | --- |

—

Declare that the provisions of Article 7(1)(b) and Article 7(2) of Regulation No 207/2009 do not preclude the publication of the mark applied for;

| — | Refer application No 01 1 4 27  507 back to the defendant so that the registration procedure may be resumed; |
| --- | --- |

—

Refer application No 01 1 4 27  507 back to the defendant so that the registration procedure may be resumed;

| — | Order the defendant to pay the costs, including the costs in respect of the appeal proceedings. |
| --- | --- |

—

Order the defendant to pay the costs, including the costs in respect of the appeal proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: the figurative mark including the word element ‘Deluxe’ for goods and services in Classes 5, 29, 30, 31, 32 and 33 — Community trade mark application No 1 1 4 27  507

Community trade mark concerned:

Decision of the Examiner: the application was rejected

Decision of the Examiner:

Decision of the Board of Appeal: the appeal was dismissed

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 7(1)(b) of Regulation No 207/2009

Pleas in law:

---
#### Lenore C. Mintz, Chairman of the Board of Education of the City of Norwalk, et al. *v.*Norwalk Teacher’s Association et al.

*Frank W. Murphy,*corporation counsel, with whom was *E. Terry Durant,*for the appellees (plaintiffs).

*Arnold J. Bai,*with whom were *Alfred J. Jennings, Jr.,*and *John A. Vigilante,*for the appellants (defendants).

Argued December 2

decided December 2, 1969

The motion by the plaintiffs to dismiss the appeal from the Superior Court in Fairfield County is granted.
# C_2016048EN.01009802.xml

| 8.2.2016 | EN | Official Journal of the European Union | C 48/98 |
| --- | --- | --- | --- |

8.2.2016

EN

Official Journal of the European Union

C 48/98

---

Order of the Civil Service Tribunal (2nd Chamber) of 17 December 2015 — López Cabeza v Commission

(Case F-76/14) (1)

1

((Civil Service - Open competition - Competition notice EPSO/AD/248/13 - Non-inclusion on the reserve list - Insufficient mark in the assessment centre tests - Action for annulment - Breach of the competition notice - Illegality of a test))

(2016/C 048/113)

Language of the case: Spanish

Parties

Parties

Applicant: Alfonso López Cabeza (Valladolid, Spain) (represented by: G. Suárez de Castro and M. Orman, lawyers)

Applicant:

Defendant: European Commission (represented by: J. Baquero Cruz and G. Gattinara)

Defendant:

Re:

Re:

Application for annulment of the decision not to include the applicant on the reserve list for Competition EPSO/AD/248/13.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as manifestly unfounded. |
| --- | --- |

1.

The action is dismissed as manifestly unfounded.

| 2. | The European Commission shall bear its own costs and is ordered to pay all the costs incurred by Mr López Cabeza. |
| --- | --- |

2.

The European Commission shall bear its own costs and is ordered to pay all the costs incurred by Mr López Cabeza.

---

(1)  OJ C 388, 3.11.2014, p. 30.

1

---
# C_2014431EN.01002602.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/26 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/26

---

Order of the President of the General Court of 4 September 2014 — Walter Klein v Commission

(Case T-297/14 R)

((Application for interim measures - State aid - National support for the generation of renewable electricity - Commission decision to open the State aid formal investigation procedure - Application for suspension of operation of a measure - Prima facie case))

(2014/C 431/46)

Language of the case: German

Parties

Parties

Applicant: Walter Klein GmbH & Co. KG (Wuppertal, Germany) (represented by: T. Volz and B. Wißmann, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian and R. Sauer, Agents)

Defendant:

Re:

Re:

Application to suspend the legal effects of the decision by which the Commission opened the State aid formal investigation procedure concerning the German law on renewable energy.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The costs are reserved. |
| --- | --- |

2.

The costs are reserved.

---
Exhibit
31.2



CERTIFICATION



I,
Mark D. Roberson, certify that:



|1. | I
    have reviewed this Amendment No. 1 on Form 10-K/A to the annual report on Form 10-K for the year ended December 31, 2018 of
    Ballantyne Strong, Inc.; and                                                                                                                                                    
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                       
|2. | Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report.



| | By: | /s/
    MARK D. ROBERSON                                                                         
| | --- | -------------------------------------------------------------------------------------------------
| |     | Mark
                                         D. Roberson
        Chief
        Financial Officer



March
29, 2019
§ 520.970 Flunixin. ( a ) *Specifications.* ( 1 ) Each 10-gram (g) packet of granules contains flunixin meglumine equivalent to 250 milligrams (mg) of flunixin.
( 2 ) Each 30-g syringe of paste contains flunixin meglumine equivalent to 1,500 mg of flunixin.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section. ( 1 ) No. 000061 for use of products described in paragraph (a).
( 2 ) No. 061133 for use of the product described in paragraph (a)(2).
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 0.5 mg per pound of body weight per day for up to 5 days.
( 2 ) *Indications for use.* For alleviation of inflammation and pain associated with musculoskeletal disorders.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[76 FR 53051, Aug. 25, 2011, as amended at 79 FR 74020, Dec. 15, 2014; 84 FR 8972, Mar. 13, 2019]
# C_2014261EN.01003801.xml

| 11.8.2014 | EN | Official Journal of the European Union | C 261/38 |
| --- | --- | --- | --- |

11.8.2014

EN

Official Journal of the European Union

C 261/38

---

Action brought on 30 May 2014 — Pshonka v Council

(Case T-381/14)

2014/C 261/63

Language of the case: English

Parties

Parties

Applicant: Viktor Pavlovych Pshonka (Moscow, Russia) (represented by: C. Constantina and J.-M. Reymond, lawyers)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | partially annul, on the basis of Article 263 of the Treaty on the Functioning of the European Union (TFEU), Council Decision 2014/119/CFSP of 5 March 2014 and Council Regulation No 208/2014 of 5 March 2014, insofar as they concern the applicant and, more specifically, order:






  — | to remove the applicant’s name from Annex I of the Council Regulation N. 208/2014 of 5 March 2014; |
| --- | --- | --- |

—

partially annul, on the basis of Article 263 of the Treaty on the Functioning of the European Union (TFEU), Council Decision 2014/119/CFSP of 5 March 2014 and Council Regulation No 208/2014 of 5 March 2014, insofar as they concern the applicant and, more specifically, order:

—

to remove the applicant’s name from Annex I of the Council Regulation N. 208/2014 of 5 March 2014;

| — | to remove the applicant’s name from Annex I of the Council Decision 2014/119/CFSP of 5 March 2014; |
| --- | --- |

—

to remove the applicant’s name from Annex I of the Council Decision 2014/119/CFSP of 5 March 2014;

| — | partially annul, on the basis of Article 263 TFEU, Council Decision 2014/119/CFSP of 5 March 2014 and Council Regulation No 208/2014 of 5 March 2014, insofar as they do not conform to the Joint Proposal; |
| --- | --- |

—

partially annul, on the basis of Article 263 TFEU, Council Decision 2014/119/CFSP of 5 March 2014 and Council Regulation No 208/2014 of 5 March 2014, insofar as they do not conform to the Joint Proposal;

| — | order the Council to bear the costs of this suit and award costs to the applicant. |
| --- | --- |

—

order the Council to bear the costs of this suit and award costs to the applicant.

Pleas in law and main arguments

Pleas in law and main arguments

In support of the action, the applicant relies on three pleas in law which are essentially identical or similar to those relied on in Case T-380/14, Pshonka v Council.

Pshonka

Council

---
§ 876.4890 Urological table and accessories. ( a ) *Identification.* A urological table and accessories is a device that consists of a table, stirrups, and belts used to support a patient in a suitable position for endoscopic procedures of the lower urinary tract. The table can be adjusted into position manually or electrically.
( b ) *Classification.* ( 1 ) Class II (special controls) for the electrically powered urological table and accessories. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 876.9.
( 2 ) Class I for the manually powered table and accessories, and for stirrups for electrically powered table. The device subject to this paragraph (b)(2) is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 61 FR 1122, Jan. 16, 1996; 63 FR 59228, Nov. 3, 1998; 66 FR 38801, July 25, 2001]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5095 Retrograde intubation device. ( a ) *Identification.* A retrograde intubation device is a prescription device used to perform retrograde intubation via the cricothyroid membrane. The device may contain or be labeled for use with guidewires and intubating catheters, in addition to needles (§ 868.5090), syringe (§ 880.5860 of this chapter), and hemostats (§ 878.4800 of this chapter).
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including the following: ( i ) Wire guide tensile, flex, fracture, and corrosion testing;
( ii ) Catheter tensile strength testing at likely points of failure;
( iii ) Catheter kink radius testing;
( iv ) Compatibility of device components that interact, including compatibility in connection, disconnection, and ability to transfer fluids;
( v ) Dimensional validation;
( vi ) Accuracy testing of markings; and
( vii ) Validation of the maximum airway pressure.
( 2 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 3 ) The device must be demonstrated to be biocompatible.
( 4 ) Labeling must include: ( i ) Instructions for use; and
( ii ) Package labels that clearly identify the minimum compatible size of endotracheal tube.
[86 FR 73678, Dec. 28, 2021]
<PAGE>
The Board of Directors
GE Global Insurance Holding Corporation:

We consent to  incorporation  by reference in the  registration  statement  (No.
33-80193) on Form S-3 of GE Global Insurance  Holding  Corporation of our report
dated  January 22, 1999,  relating to the  consolidated  statements of financial
position of GE Global  Insurance  Holding  Corporation  and  subsidiaries  as of
December 31, 1998 and 1997, and the related consolidated statements of earnings,
stockholder's  equity  and cash  flows for each of the  years in the  three-year
period ended December 31, 1998, and all related schedules,  which report appears
in the  December  31, 1998,  annual  report on Form 10-K of GE Global  Insurance
Holding Corporation.


                                                                        KPMG LLP


Kansas City, Missouri
March 26, 1999